Faster Decisions Start With AI-Driven Clinical Review
Clinical trials generate more data than ever before.
From EDC systems, laboratory data, clinical trial management systems (CTMS), and safety data to operational and real-world sources, the volume of information flowing through clinical programs continues to grow.
At the same time, AI is creating new opportunities to analyze that information at a scale that wasn’t previously possible. Organizations can no longer afford to treat quality as something that gets evaluated at the end of a study. Increasingly, they need to identify risks, signals, and data issues while there is still time to act.
That’s creating a new challenge for clinical teams. The industry’s problem is no longer access to data. It’s deciding where experts should focus their attention.
More Data Hasn’t Made Review Easier
For years, life sciences organizations have invested heavily in data platforms, automation, and analytics. Yet clinical trial delays remain stubbornly persistent.
According to the Tufts Center...
Copyright of this story solely belongs to perficient.com. To see the full text click HERE
